0ADR Stock Overview

Develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. More details

0ADR fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	5/6
Financial Health	5/6
Dividends	0/6

Rewards

Earnings are forecast to grow 5.85% per year

Earnings grew by 250.8% over the past year

Risk Analysis

Shares are highly illiquid

Has a high level of debt

Significant insider selling over the past 3 months

My Notes

Capture your thoughts, links and company narrative

Insulet Corporation Competitors

Smith & Nephew

LSE:SN.

UK£8.8b

NIOX Group

AIM:NIOX

UK£250.7m

ConvaTec Group

LSE:CTEC

UK£4.9b

EKF Diagnostics Holdings

AIM:EKF

UK£112.5m

Price History & Performance

Summary of share price highs, lows and changes for Insulet
Historical stock prices
Current Share Price	US$284.16
52 Week High	US$284.16
52 Week Low	US$284.16
Beta	1.23
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	0%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	0ADR	GB Medical Equipment	GB Market
7D	n/a	-1.4%	2.2%
1Y	n/a	-5.7%	13.7%

Return vs Industry: Insufficient data to determine how 0ADR performed against the UK Medical Equipment industry.

Return vs Market: Insufficient data to determine how 0ADR performed against the UK Market.

Price Volatility

Is 0ADR's price volatile compared to industry and market?
0ADR volatility
0ADR Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	6.8%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.3%
10% least volatile stocks in GB Market	2.6%

Stable Share Price: 0ADR's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: Insufficient data to determine 0ADR's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2000	3,000	Jim Hollingshead	www.insulet.com

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company’s Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally.

Insulet Corporation Fundamentals Summary

How do Insulet's earnings and revenue compare to its market cap?
0ADR fundamental statistics
Market cap	US$19.94b
Earnings (TTM)	US$420.90m
Revenue (TTM)	US$1.98b

47.4x

P/E Ratio

10.1x

P/S Ratio

Is 0ADR overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0ADR income statement (TTM)
Revenue	US$1.98b
Cost of Revenue	US$595.20m
Gross Profit	US$1.39b
Other Expenses	US$967.80m
Earnings	US$420.90m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Feb 20, 2025

Earnings per share (EPS)	6.00
Gross Margin	70.00%
Net Profit Margin	21.22%
Debt/Equity Ratio	123.4%

How did 0ADR perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/02/12 05:31
End of Day Share Price	2025/02/11 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Insulet Corporation is covered by 58 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Anand Vankawala	Avondale Partners
Jeffrey Johnson	Baird
null null	Baird